Drugs / NC 6300
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03168061 | Jun 2017 → Jul 2020 | soft tissue sarcoma | NanoCarrier Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NC 6300 | “NC-6300 is a novel epirubicin (EPI) drug conjugated polymeric micelle developed using cutting-edge micellar nanoparticle technology.” PMID 35920783 ↗ Oct 20221“Drug: NC 6300” NCT03168061 ↗ |
| Modality | Other / unclassified | “NC-6300 is a novel epirubicin (EPI) drug conjugated polymeric micelle developed using cutting-edge micellar nanoparticle technology.” PMID 35920783 ↗ Oct 2022 |
| Route | Intravenous | “Patients were dosed using the recommended dose of 150 mg/m2 intravenously (IV) once every 3 weeks.” PMID 35920783 ↗ Oct 2022 |